CTNM Contineum Therapeutics
- 16.380
- -0.100-0.61%
- 16.380
- 0.0000.00%
Contineum Therapeutics News
Contineum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Huhn Stephen L.
Contineum Therapeutics | 10-Q: Quarterly report
Contineum Therapeutics | 8-K/A: Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Contineum Therapeutics | 8-K: Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Contineum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Boyce Sarah
Contineum Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Boyce Sarah
Contineum Therapeutics | 8-K: Current report
Contineum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Healy John Stephen
Contineum Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Healy John Stephen
Contineum Therapeutics | 8-K: Current report
Contineum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Stengone Carmine N.
Contineum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Slover Peter T
Contineum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Lorrain Daniel S.
Contineum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Huhn Stephen L.
Contineum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ignelzi Troy A.
Contineum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ware Olivia C
Contineum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Lyons-Williams Lori
Contineum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Brady Todd R.
Contineum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Schimmelpennink Evert B.
Contineum Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Ignelzi Troy A.
Analysis
Price Target
No Data
No Data